Lab21 Offering Companion Testing to Personalize ALK Inhibitors for NSCLC Patients
February 22, 2012
Lab21 Offering Companion Testing to Personalize ALK Inhibitors for NSCLC Patients
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Case Study Suggests FISH Test May Miss Some Patients Who Could Benefit from Crizotinib
September 12, 2012 / Pharmacogenomics Reporter - Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Focusing on Personalized Medicine, Pfizer Reports PGx Data for Several Oncologics at ASCO
June 9, 2010 / Pharmacogenomics Reporter - Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori
June 6, 2012 / Pharmacogenomics Reporter